- Previous Close
22.75 - Open
22.48 - Bid 22.21 x 100
- Ask 22.50 x 100
- Day's Range
22.31 - 22.81 - 52 Week Range
16.53 - 41.02 - Volume
54,429 - Avg. Volume
1,585,212 - Market Cap (intraday)
2.004B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.44 - Earnings Date Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.80
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
www.fortrea.comRecent News: FTRE
View More
Performance Overview: FTRE
Trailing total returns as of 11/12/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FTRE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FTRE
View MoreValuation Measures
Market Cap
2.04B
Enterprise Value
3.14B
Trailing P/E
--
Forward P/E
384.62
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.68
Price/Book (mrq)
1.35
Enterprise Value/Revenue
1.05
Enterprise Value/EBITDA
441.77
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.08%
Return on Assets (ttm)
-1.04%
Return on Equity (ttm)
-13.59%
Revenue (ttm)
2.98B
Net Income Avi to Common (ttm)
-217.9M
Diluted EPS (ttm)
-2.44
Balance Sheet and Cash Flow
Total Cash (mrq)
105.3M
Total Debt/Equity (mrq)
79.74%
Levered Free Cash Flow (ttm)
368.2M
Research Analysis: FTRE
View MoreCompany Insights: FTRE
FTRE does not have Company Insights
Research Reports: FTRE
View MoreFortrea Earnings: Stock Soars on Strong Execution; Positive Long-Term Outlook
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
RatingPrice TargetLowering target price to $18.00
FORTREA HOLDINGS INC has an Investment Rating of HOLD; a target price of $18.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about FTRE?
FORTREA HOLDINGS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $19.00
FORTREA HOLDINGS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target